The seroprevalence of HCV among injecting drug users in the years 2004–2008 in Slovakia
Authors: K. Gazdíková, †F. Gazdík, I. Kajaba, D. Hučková, Ľ. Okruhlica, D. Farkašová
Authors - sphere of activity: 1Fakulta ošetrovateľstva a zdravotníckych odborných štúdií Slovenskej zdravotníckej univerzity Bratislava, Slovenská republika, rektorka Dr. h. c. prof. PhDr. Dana Farkašová, CSc.; 2Oddelenie imunológie a imunotoxikológie Slovenskej zdravotníckej univerzity Bratislava, Slovenská republika, rektorka Dr. h. c. prof. PhDr. Dana Farkašová, CSc.; 3HPL spol. s r.o., Bratislava, Slovenská republika, riaditeľ MUDr. Juraj Hanzen; 4Inštitút drogových závislostí, Centrum pre liečbu drogových závislostí Bratislava, Slovenská republika, riaditeľ MUDr. Ľubomír Okruhlica, PhD.
Article: Vnitř Lék, 2012, 58(3): 179-182
Category: Original Contributions
Number of articles displayed: 265x
Virus of hepatitis C (HCV) is the leading cause of chronic liver disease, including cirrhosis and cancer, and the most common indication for liver transplantation. In industrialised countries, injecting drug use is currently the most important risk factor for infection with hepatitis C, resulting in high prevalence of hepatitis C among injecting drug users (IDUs). The aim of the study was to assess the seroprevalence of HCV infection and distribution of genotypes among IDUs in the years 2004–2008.
Probands and methods:
A total number of 846 probands, both sexes (590 males and 256 females) with mean age from 24 to 29 years were investigated in the years 2004–2008. Standard virological tests were performed.
The seroprevalence of anti-HCV positivity during the years 2004–2008 were in range 34–78% and positivity of HCV RNA assessed by PCR method were in range 17–71%. The genotypes distribution was in favour of genotype 3.
In Slovakia IDUs represent risk group with high prevalence of hepatitis C. These results are comparable to those published in other European countries.
prevalence – hepatitis C virus (HCV) – risk group of injecting drug users – HCV genotypes – distribution
The full wording of this article is available only to registered users. Plese register and you can read this article immediately.
If you are a subscriber, log in and enter the subscriber code from your magazine cover.
If you are not a subscriber, log in for unlimited access to older editions.
Tento článek si můžete přečíst pokud si aktivujete Premium účet.
- Practice guideline and trends for immunosuppressive treatment of glomerulonephritides according to KDIGO (Clinical Practice Guideline for Glomerulonephritis) | views: 175
- Aortic regurgitation | views: 123
- Opinion of the Czech Atherosclerosis Society‘s committee (CSAT) on the ESC/EAS guidlines related to the diagnostics and treatment of dyslipidemias issued in 2011 | views: 95
- Ischemic peripheral arterial disease and recurrent iliofemoral venous thrombosis in a 24-year-old man with antiphospholipid syndrome | views: 81
- Changes in weight and diabetes compensation (HbA1c) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic – BIBY-I study (observations lasting 3 to 12 months) | views: 53
- Current trends in treatment and follow-up of patients with differentiated thyroid carcinoma – experience with the use of recombinant human thyrotropin | views: 46
- Heart transplantation and the subsequent treatment of AL amyloidosis | views: 37
- Risk factors for diabetic retinopathy | views: 36
- Syncope as first and only sign of left atrial myxoma | views: 31
- Patophysiology of diabetic retinopathy | views: 29